{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:07:47Z","timestamp":1789787267220,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93483-7","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:26:08Z","timestamp":1742030768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Empagliflozin demonstrates neuroprotective and cardioprotective effects by reducing ischemia\/reperfusion damage in rat models of ischemic stroke and myocardial infarction"],"prefix":"10.1038","volume":"15","author":[{"given":"Wangde","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Carreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niema M.","family":"Pahlevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kloner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"1","key":"93483_CR1","doi-asserted-by":"publisher","first-page":"9544","DOI":"10.1038\/s41598-021-89149-9","volume":"11","author":"JM Seefeldt","year":"2021","unstructured":"Seefeldt, J. M. et al. Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats. Sci. Rep. 11 (1), 9544 (2021).","journal-title":"Sci. Rep."},{"issue":"Suppl 1","key":"93483_CR2","doi-asserted-by":"publisher","first-page":"i84","DOI":"10.1093\/eurheartjsupp\/suae008","volume":"26","author":"GA Tavecchia","year":"2024","unstructured":"Tavecchia, G. A., Gualini, E., Sacco, A. & Oliva, F. The role of sodium-glucose co-transporter 2 inhibitors in myocardial infarction: available evidence and future perspectives. Eur. Heart J. Suppl. 26 (Suppl 1), i84\u2013i87 (2024).","journal-title":"Eur. Heart J. Suppl."},{"issue":"11","key":"93483_CR3","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1016\/j.clinthera.2020.09.008","volume":"42","author":"FA Al Hamed","year":"2020","unstructured":"Al Hamed, F. A. & Elewa, H. Potential therapeutic effects of sodium Glucose-linked cotransporter 2 inhibitors in stroke. Clin. Ther. 42 (11), e242\u2013e249 (2020).","journal-title":"Clin. Ther."},{"issue":"1","key":"93483_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s42003-022-03605-4","volume":"5","author":"M Takashima","year":"2022","unstructured":"Takashima, M. et al. Low-dose sodium-glucose cotransporter 2 inhibitor ameliorates ischemic brain injury in mice through pericyte protection without glucose-lowering effects. Commun. Biol. 5 (1), 653 (2022).","journal-title":"Commun. Biol."},{"issue":"1","key":"93483_CR5","doi-asserted-by":"publisher","first-page":"15364","DOI":"10.1038\/s41598-021-94945-4","volume":"11","author":"WH Tsai","year":"2021","unstructured":"Tsai, W. H. et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci. Rep. 11 (1), 15364 (2021).","journal-title":"Sci. Rep."},{"issue":"1","key":"93483_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12933-024-02174-6","volume":"23","author":"E Vercalsteren","year":"2024","unstructured":"Vercalsteren, E. et al. The SGLT2 inhibitor empagliflozin promotes post-stroke functional recovery in diabetic mice. Cardiovasc. Diabetol. 23 (1), 88 (2024).","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"93483_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-020-0994-y","volume":"19","author":"KA Connelly","year":"2020","unstructured":"Connelly, K. A. et al. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc. Diabetol. 19 (1), 13 (2020).","journal-title":"Cardiovasc. Diabetol."},{"issue":"11","key":"93483_CR8","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.3390\/jcm12113815","volume":"12","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi, H. et al. Sodium glucose Cotransporter-2 inhibitor empagliflozin increases antioxidative capacity and improves renal function in diabetic rats. J. Clin. Med. 12 (11), 3815 (2023).","journal-title":"J. Clin. Med."},{"issue":"12","key":"93483_CR9","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/s41440-019-0326-3","volume":"42","author":"S Kim","year":"2019","unstructured":"Kim, S., Jo, C. H. & Kim, G. H. Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertens. Res. 42 (12), 1905\u20131915 (2019).","journal-title":"Hypertens. Res."},{"key":"93483_CR10","doi-asserted-by":"crossref","unstructured":"Sharp, P. & Villano, J. S. The Laboratory Rat. 2nd Edition. Published December 11, by CRC Press. ISBN 9781439829868. (2012).","DOI":"10.1201\/b13862"},{"key":"93483_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/01.STR.20.1.84","volume":"20","author":"EL Zea Longa","year":"1989","unstructured":"Zea Longa, E. L., Weinstein, P. R., Carlson, S. & Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84\u201391 (1989).","journal-title":"Stroke"},{"issue":"3","key":"93483_CR12","first-page":"38","volume":"10","author":"C Nouraee","year":"2019","unstructured":"Nouraee, C. et al. A brief review of Edema-Adjusted infarct volume measurement techniques for rodent focal cerebral ischemia models with practical recommendations. J. Vasc Interv Neurol. 10 (3), 38\u201345 (2019).","journal-title":"J. Vasc Interv Neurol."},{"issue":"12","key":"93483_CR13","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0196-9781(02)00262-0","volume":"23","author":"D Reglodi","year":"2002","unstructured":"Reglodi, D. et al. Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 23 (12), 2227\u20132234 (2002).","journal-title":"Peptides"},{"issue":"4","key":"93483_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/107424840300800405","volume":"8","author":"W Dai","year":"2003","unstructured":"Dai, W. & Kloner, R. A. Effects of acetaminophen on myocardial infarct size in rats. J. Cardiovasc. Pharmacol. Ther. 8 (4), 277\u2013284 (2003).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"93483_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-60761-705-1_7","volume-title":"Stem Cells for Myocardial Regeneration","author":"W Dai","year":"2010","unstructured":"Dai, W. & Kloner, R. A. Experimental cell transplantation therapy in rat myocardial infarction model including nude rat Preparation. In: (ed Lee, R. J.) Stem Cells for Myocardial Regeneration, Methods in Molecular Biology\u2122. Springer; (2010). Volume 660, Part 2, 99\u2013109."},{"issue":"4","key":"93483_CR16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00213-023-06341-7","volume":"240","author":"I Pi\u0105tkowska-Chmiel","year":"2023","unstructured":"Pi\u0105tkowska-Chmiel, I. et al. Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacol. (Berl). 240 (4), 983\u20131000 (2023).","journal-title":"Psychopharmacol. (Berl)"},{"key":"93483_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","volume":"43","author":"RG Bdel-Latif","year":"2020","unstructured":"Bdel-Latif, R. G., Rifaai, R. A. & Amin, E. F. Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1\u03b1\/VEGF signaling pathway. Arch. Pharm. Res. 43, 514\u2013525 (2020).","journal-title":"Arch. Pharm. Res."},{"issue":"5","key":"93483_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/fcp.12548","volume":"34","author":"EF Amin","year":"2020","unstructured":"Amin, E. F., Rifaai, R. A. & Abdel-Latif, R. G. Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Fundam Clin. Pharmacol. 34 (5), 548\u2013558 (2020).","journal-title":"Fundam Clin. Pharmacol."},{"key":"93483_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0072-9752(08)01914-3","volume":"92","author":"A Kunz","year":"2009","unstructured":"Kunz, A. & Iadecola, C. Cerebral vascular dysregulation in the ischemic brain. Handb. Clin. Neurol. 92, 283\u2013305 (2009).","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"93483_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4070\/kcj.2020.0303","volume":"51","author":"SY Lee","year":"2021","unstructured":"Lee, S. Y. et al. Sodium\/glucose Co-Transporter 2 inhibitor, Empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction. Korean Circ. J. 51 (3), 251\u2013262 (2021).","journal-title":"Korean Circ. J."},{"key":"93483_CR21","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.redox.2022.102288","volume":"52","author":"C Cai","year":"2022","unstructured":"Cai, C. et al. Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway. Redox Biol. 52, 102288 (2022).","journal-title":"Redox Biol."},{"key":"93483_CR22","doi-asserted-by":"publisher","first-page":"110642","DOI":"10.1016\/j.mce.2019.110642","volume":"501","author":"Q Lu","year":"2020","unstructured":"Lu, Q. et al. Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway. Mol. Cell. Endocrinol. 501, 110642 (2020).","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"93483_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"S Lahnwong","year":"2020","unstructured":"Lahnwong, S. et al. Acute Dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovasc. Diabetol. 19 (1), 91 (2020).","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"93483_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","volume":"17","author":"AA Sayour","year":"2019","unstructured":"Sayour, A. A. et al. Acute Canagliflozin treatment protects against in vivo myocardial ischemia\/reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J. Transl Med. 17 (1), 127 (2019).","journal-title":"J. Transl Med."},{"issue":"6","key":"93483_CR25","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk, G. D. & Verma, S. Mechanisms of cardiovascular benefits of sodium glucose Co-Transporter 2 (SGLT2) inhibitors: A State-of-the-Art review. JACC Basic. Transl Sci. 5 (6), 632\u2013644 (2020).","journal-title":"JACC Basic. Transl Sci."},{"issue":"16","key":"93483_CR26","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.3390\/ijms22168786","volume":"22","author":"W Durante","year":"2021","unstructured":"Durante, W., Behnammanesh, G. & Peyton, K. J. Effects of Sodium-Glucose Co-Transporter 2 inhibitors on vascular cell function and arterial remodeling. Int. J. Mol. Sci. 22 (16), 8786 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"93483_CR27","doi-asserted-by":"publisher","first-page":"e015502","DOI":"10.1161\/JAHA.119.015502","volume":"9","author":"RA Kloner","year":"2020","unstructured":"Kloner, R. A. Stunned and hibernating myocardium: where are we nearly 4 decades later?? J. Am. Heart Assoc. 9 (3), e015502 (2020).","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"93483_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-024-02150-0","volume":"23","author":"PT Htoo","year":"2024","unstructured":"Htoo, P. T. et al. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc. Diabetol. 23 (1), 57 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"93483_CR29","first-page":"100261","volume":"26","author":"FB Rivera","year":"2023","unstructured":"Rivera, F. B. et al. Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis. Am. Heart J. Plus. 26, 100261 (2023).","journal-title":"Am. Heart J. Plus"},{"issue":"5","key":"93483_CR30","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1161\/01.CIR.87.5.1642","volume":"87","author":"Y Li","year":"1993","unstructured":"Li, Y. & Kloner, R. A. The cardioprotective effects of ischemic \u2018preconditioning\u2019 are not mediated by adenosine receptors in rat hearts. Circulation 87 (5), 1642\u20131648 (1993).","journal-title":"Circulation"},{"issue":"2","key":"93483_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1074248407300897","volume":"12","author":"J Dow","year":"2007","unstructured":"Dow, J. & Kloner, R. A. Postconditioning does not reduce myocardial infarct size in an in vivo regional ischemia rodent model. J. Cardiovasc. Pharmacol. Ther. 12 (2), 153\u2013163 (2007).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"9","key":"93483_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4239\/wjd.v13.i9.683","volume":"13","author":"V Quentin","year":"2022","unstructured":"Quentin, V., Singh, M. & Nguyen, L. S. A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena. World J. Diabetes. 13 (9), 683\u2013695 (2022).","journal-title":"World J. Diabetes"},{"issue":"6","key":"93483_CR33","first-page":"e40602","volume":"15","author":"K Ravendran","year":"2023","unstructured":"Ravendran, K. et al. The use of empagliflozin post myocardial infarction. Cureus 15 (6), e40602 (2023).","journal-title":"Cureus"},{"issue":"3","key":"93483_CR34","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/neurolint14030044","volume":"14","author":"YI Sysoev","year":"2022","unstructured":"Sysoev, Y. I. et al. Changes in brain electrical activity after transient middle cerebral artery occlusion in rats. Neurol. Int. 14 (3), 547\u2013560 (2022).","journal-title":"Neurol. Int."},{"issue":"24","key":"93483_CR35","doi-asserted-by":"publisher","first-page":"e036146","DOI":"10.1161\/JAHA.124.036146","volume":"13","author":"P Liu","year":"2024","unstructured":"Liu, P. et al. Electrophysiological signatures in global cerebral ischemia: neuroprotection via chemogenetic Inhibition of CA1 pyramidal neurons in rats. J. Am. Heart Assoc. 13 (24), e036146 (2024).","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"93483_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.36660\/abc.20200121","volume":"117","author":"N Amini","year":"2021","unstructured":"Amini, N. et al. Improve baroreflex sensitivity and nucleus tractus solitarius electrical activity in renal Ischemia-Reperfusion injury. Arq. Bras. Cardiol. 117 (2), 290\u2013297 (2021).","journal-title":"Arq. Bras. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93483-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T09:26:11Z","timestamp":1742030771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93483-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93483"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93483-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8986"}}